Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry by Riera-Mestre, Antoni et al.
RESEARCH Open Access
Natural history of patients with venous
thromboembolism and hereditary
hemorrhagic telangiectasia. Findings from
the RIETE registry
Antoni Riera-Mestre1,2* , José María Mora-Luján1, Javier Trujillo-Santos3, Jorge Del Toro4, José Antonio Nieto5,
José María Pedrajas6, Raquel López-Reyes7, Silvia Soler8, Aitor Ballaz9, Pau Cerdà1, Manel Monreal10 and the RIETE
Investigators
Abstract
Background: Limited data exist about the clinical presentation, ideal therapy and outcomes of patients with
hereditary hemorrhagic telangiectasia (HHT) who develop venous thromboembolism (VTE).
Methods: We used the data in the RIETE Registry to assess the clinical characteristics, therapeutic approaches and
clinical outcomes during the course of anticoagulant therapy in patients with HHT according to initial presentation
as pulmonary embolism (PE) or deep venous thrombosis (DVT).
Results: Of 51,375 patients with acute VTE enrolled in RIETE from February 2009 to January 2019, 23 (0.04%) had
HHT: 14 (61%) initially presented with PE and 9 (39%) with DVT alone. Almost half (47.8%) of the patients with VTE
had a risk factor for VTE. Most PE and DVT patients received low-molecular-weight heparin for initial (71 and 100%,
respectively) and long-term therapy (54 and 67%, respectively). During anticoagulation for VTE, the rate of bleeding
events (major 2, non-major 6) far outweighed the rate of VTE recurrences (recurrent DVT 1): 50.1 bleeds per 100
patient-years (95%CI: 21.6-98.7) vs. 6.26 recurrences (95%CI: 0.31–30.9; p = 0.020). One major and three non-major
bleeding were epistaxis. No patient died of bleeding. One patient died shortly after being diagnosed with acute PE.
Conclusions: During anticoagulation for VTE in HHT patients, there were more bleeding events than VTE
recurrences. Most bleeding episodes were non-major epistaxis.
Keywords: Deep venous thrombosis, Hemorrhagic hereditary telangiectasia, Pulmonary embolism, Rare diseases,
Venous thromboembolism
Introduction
Hereditary hemorrhagic telangiectasia (HHT) or Rendu-
Osler-Weber disease is a rare vascular genetic disorder
with an estimated prevalence of one in 6000 individuals
[1, 2]. Patients with HHT have cutaneous telangiectasia,
mostly in the fleshy part of the hands, or in the oral,
nasal or gastrointestinal (GI) mucosa, and large
arteriovenous malformations (AVMs), mostly in the
lungs or liver [3, 4]. These patients may suffer from
many complications including bleeding, anemia, iron de-
ficiency, stroke and high-output heart failure [4–6].
The diagnosis of HHT is established on clinical cri-
teria, according to the Curaçao criteria: recurrent epi-
staxis, cutaneous/mucosal telangiectasia, visceral
involvement, and a first line family member with HHT
[7]. The diagnosis may be further confirmed by the iden-
tification of causative mutations mostly in either the
ENG (endoglin) or the ACVRL1 (activin A receptor type
II-like 1) genes coding for endoglin and activin receptor-
like kinase-1, respectively [2]. These proteins are
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involved in the vascular signaling pathway of the trans-
forming growth factor (TGF)-beta family [2, 8]. Recur-
rent epistaxis is the most common symptom, appearing
in around 95% of HHT patients by 50 years of age [3, 4,
9]. Although recurrent bleeding events are the hallmark,
some patients with HHT may also develop venous
thromboembolism (VTE) [9–11]. HHT patients with
acute venous thromboembolism (VTE) are perceived to
be at high risk for major bleeding if anticoagulant ther-
apy is prescribed, but the evidence on this issue is scarce
and based on online interviews [12, 13].
The RIETE (Registro Informatizado Enfermedad
TromboEmbólica) registry is an ongoing, multicenter,
observational registry of consecutive patients with ob-
jectively confirmed acute VTE (ClinicalTrials.gov identi-
fier: NCT02832245). Data from this registry have been
used to evaluate outcomes after acute VTE, such as the
frequency of recurrent VTE, major bleeding or mortal-
ity, and risk factors for these outcomes [14–16]. The ra-
tionale and methodology of RIETE have been published
elsewhere [17]. In the current study, we aimed to assess
the clinical characteristics, therapeutic approaches and
clinical outcomes of patients with HHT and VTE, ac-
cording to initial presentation as pulmonary embolism
(PE) or deep venous thrombosis (DVT).
Methods
Inclusion criteria
Consecutive patients with acute, symptomatic DVT or
PE confirmed by objective tests (compression ultrason-
ography or contrast venography for DVT; helical CT-
scan of the chest, ventilation-perfusion lung scintigraphy
or angiography for PE) were enrolled in RIETE. Patients
were excluded if they were currently participating in a
blind therapeutic clinical trial. All patients (or their rela-
tives) provided written or oral consent for participation
in the registry, in accordance with local ethics commit-
tee requirements.
Study design
For this study, only patients with HHT were considered.
This information was added to the RIETE data abstrac-
tion forms in February 2009. Therefore, only patients re-
cruited after this date were eligible for the current study.
Collected data were appropriately made anonymous and
each patient was identified by a unique alphanumeric
identification code. HHT patients were divided accord-
ing to VTE index event as PE or DVT. Primary outcome
was the risk for VTE recurrences and major or non-
major bleeding occurring during the course of anticoa-
gulation. Secondary outcomes were fatal PE and fatal
bleeding. Bleeding events were classified as ‘major’ if
they were overt and required transfusion of two or more
red blood cell units, or were retroperitoneal, spinal or
intracranial. All clinically evident bleeding not consid-
ered major, were classified as ‘non-major’. Fatal PE, in
the absence of autopsy, was defined as any death appear-
ing < 10 days after PE diagnosis, in the absence of any al-
ternative cause of death. Fatal bleeding was defined as
any death occurring < 10 days after a major bleeding epi-
sode, in the absence of any alternative cause of death.
For preparation of this manuscript, we followed the
Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) statement guidelines for obser-
vational cohort studies [18].
Study variables
The following parameters were recorded in RIETE: pa-
tient’s baseline characteristics; clinical status including
any coexisting or underlying conditions, recent major
bleeding, anemia or renal insufficiency; risk factors for
VTE; the treatment received upon VTE diagnosis; con-
comitant drugs and the outcomes during the course of
therapy. For normotensive patients with PE, stratifica-
tion using the simplified version of the Pulmonary Em-
bolism Severity Index (sPESI) was assessed [15].
Immobilized patients were defined as non-surgical pa-
tients who had been immobilized (i.e., total bed rest with
or without bathroom privileges) for ≥4 days in the 2-
month period prior to VTE diagnosis. Surgical patients
were defined as those who had undergone an operation
in the 2 months prior to VTE. Active cancer was defined
as newly diagnosed cancer (< 3 months before) or when
receiving anti-neoplastic treatment of any type (i.e., sur-
gery, chemotherapy, radiotherapy or hormonal therap-
ies). Recent bleeding was considered in those patients
suffering major bleeding < 30 days prior to VTE. Anemia
was defined as hemoglobin levels < 13 g/dL for men
and < 12 g/dL for women.
HHT additional information
When preparing this study, we attempted to gather as
much specific information on HHT as possible, through
personal communication with the attending doctors.
The study coordinating center contacted with the inves-
tigators and tried to retrospectively calculate the Epi-
staxis Severity Score (ESS) at the index VTE event. ESS
is an on-line tool that estimates the severity of epistaxis
according to clinical data occurring during last 3
months. Epistaxis is considered moderate or severe if
ESS results > 4 or > 7 points, respectively [19]. We also
attempted to assess the genetic study for HHT, specific-
ally for mutations in ENG or ACVRL1 genes, and infor-
mation about the Curaçao criteria [2, 7, 8].
Treatment and follow-up
Patients were managed according to the clinical practice
of each participating hospital (i.e., there was no
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standardization of treatment). The type, dose and dur-
ation of anticoagulant therapy were recorded. After VTE
diagnosis, all patients were followed-up in the outpatient
clinic for at least 3 months. During each visit, any signs
or symptoms suggesting VTE recurrences or bleeding
complications were noted. Each episode of clinically sus-
pected recurrent VTE was investigated by using diagnos-
tic tests as appropriate. Most outcomes were classified
as reported by the clinical centers. However, if staff at
the coordinating center were uncertain how to classify a
reported outcome, that event was reviewed by a central
adjudicating committee (less than 10% of events).
Statistical analysis
Categorical variables were compared between PE and
DVT patients with HHT using the chi-square test (two-
sided) and Fisher’s Exact Test (two-sided). Odds ratio
(and its 95% confidence interval) was calculated for cat-
egorical variables. Continuous variables were compared
using Student t test. The incidence rate of adverse events
was calculated as events per 100 patient-years of treat-
ment and compared, according to the initial presentation
of the VTE episode (PE vs. DVT), as rate ratios, both
with a 95% confidence interval. A P-value of < 0.05 was
chosen as the cut off for statistical significance. Statis-
tical analyses were conducted using SPSS for Windows
Release (version 20, SPSS Inc. Chicago, Illinois).
Results
Of 51,375 patients enrolled in RIETE from February
2009 to January 2019, 23 (0.04%) had HHT. Of these, 13
(56.5%) were male, mean age was 61 ± 17 years, 14 (61%)
presented initially with PE and 9 (39%) presented with
DVT alone. Eighteen patients (78%) had a history of re-
current epistaxis, and three (13%) had suffered a major
bleeding (all epistaxis) in the last 30 days before the
index VTE event. There was available information to cal-
culate the ESS in 16 (69%) patients, and mean ESS was
4.4 ± 2.4 (0. 9-8.4) points. Genetic study was positive for
ENG in 5 (22%) patients, for ACVRL1 in 2 (9%) and one
(4.5%) patient had negative results (but had 3 of 4 Cura-
çao criteria).
Six patients (26%) developed the VTE after being
immobilized for ≥4 days (because of decompensated
chronic lung disease 2, trauma 2, ischemic stroke 1,
pneumonia 1), two (9%) after undergoing surgery (hernia
disc repair 1, hip fracture 1), one patient (4.5%) had can-
cer and two (9%) had a history of prior VTE. Only three
patients had received prophylaxis before the index VTE:
two patients admitted in the hospital because of decom-
pensated chronic lung disease and one patient with hip
fracture. Twelve (52%) patients had anemia at baseline,
six (26%) had creatinine clearance levels < 60mL/min,
three (13%) had angiodysplasia in the GI tract and one
(4.5%) patient had a GI ulcer. All patients had normal
prothrombin test and activated partial thromboplastin
time. There were no significant differences in the clinical
characteristics between patients who initially presented
with PE or DVT. All 14 patients initially presenting with
PE were admitted in hospital and 7 (50%) were consid-
ered to be at high risk according to sPESI score
(Table 1).
Median duration of anticoagulant therapy was 203
days in patients with PE and 164 days in those with
DVT. Most (71%) PE and all (100%) DVT patients were
initially treated with low-molecular-weight heparin
(LMWH), but four (29%) and two (22%) patients re-
spectively received less than 100 IU/kg/day. Among the
remaining patients with PE, two (14%) were prescribed
unfractionated heparin, one (7%) rivaroxaban and one
(7%) patient received an inferior vena cava filter without
anticoagulant therapy. For long-term therapy, 7 (54%)
PE patients and 6 (67%) DVT patients continued on
long-term LMWH therapy, but one (8%) and two (22%)
of these patients received less than 100 IU/kg/day, re-
spectively. Among the remaining patients, five (38%) and
three (33%) switched to vitamin K antagonists (VKAs),
respectively, and one (8%) PE patient continued on rivar-
oxaban (Table 2).
During the course of anticoagulation, (mean, 260 ±
254 days for PE and 243 ± 195 days for DVT), the rate of
bleeding events (major bleeding 2 episodes, non-major
6) far outweighed the rate of VTE recurrences (recurrent
DVT one episode): 50.1 bleeds per 100 patient-years
(95%CI: 21.6-98.7) vs. 6.26 recurrences (95%CI: 0.31–
30.9; p = 0.020). One patient had a major bleeding in the
GI tract 534 days after PE diagnosis while receiving
VKAs, and one patient had a major epistaxis 32 days
after the diagnosis of DVT while receiving LMWH at <
100 IU/kg/day. Three non-major bleeds were epistaxis.
All four patients with epistaxis had an ESS > 4. No pa-
tient died of bleeding. Among DVT patients, one patient
presented a DVT recurrence 227 days after the diagno-
sis, while receiving vitamin K antagonists. One patient
died of respiratory insufficiency due to hospital-acquired
pneumonia 4 days after being diagnosed with acute PE,
while receiving unfractionated heparin. She did not
undergo repeat tests to exclude recurrent PE, so we can-
not rule out the diagnosis of fatal PE (Table 3).
Discussion
Since HHT is a rare disorder, the natural history of VTE
in these patients, and the optimal therapy are not well
known. The only two studies that analyze the effect of
anticoagulation in HHT patients were not based on ob-
jectively confirmed diagnosis and outcomes of VTE but
on on-line surveys [12, 13]. The first one was an on-line
questionnaire about the use of antiplatelet or
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anticoagulant agents in HHT patients [12]. A worsening
of their usual epistaxis was referred in 86 (57.3%) of 150
patients with HHT who received anticoagulant therapy
for different reasons [12]. In the second study, 20% of 20
patients with self-reported diagnosis of VTE who re-
ceived anticoagulant therapy had to withdraw anticoagu-
lation because of bleeding [13].
Our findings, obtained from the largest series of
HHT patients with objectively confirmed VTE, reveal
that one in every 3 (35%) patients bled during the
course of anticoagulant therapy, though no bleed was
fatal. This may be due to the fact that most bleeds
came from nasal or GI tract telangiectasia and not
from large vascular malformations (i.e. in the liver,
lung or brain), that are common in HHT patients.
The ESS seems to detect those patients at an in-
creased risk to develop epistaxis, as all four patients
with epistaxis during anticoagulation had a ESS > 4.
ENT management to optimize measures to reduce
epistaxis could allow to better tolerate anticoagulation
[3, 20]. Other options, such as tranexamic acid, top-
ical or systemic estrogens, thalidomide or bevacizu-
mab, should be weighted against the risk of VTE for
these drugs [3, 21–24].
Table 1 Clinical characteristics of 23 patients with HHT and acute VTE
Pulmonary embolism Deep vein thrombosis Odds ratio (95% CI) /
P value
Patients, N 14 9
Clinical characteristics,
Male gender 6 (43%) 7 (78%) 0.21 (0.03–1.43)
Mean age (years±SD) 60 ± 16 62 ± 19 P = 0.708
Mean body weight (kg ± SD) 87 ± 28 72 ± 9.7 P = 0.145
Data on HHT,a
Spontaneous, recurrent epistaxis (n = 18) 12 (86%) 6 (67%)
Epistaxis severity score (n = 9 and 7) 3.5 (0. 9-8.4; ±2.1) 5.4 (2. 7-8.1;±2.3) P = 0.097
ESS > 4 3 (21%) 4 (44%) P = 0.615
ESS > 7 1 (7%) 3 (33%) P = 0.262
Genetic study (n = 11)
ENG mutations 2 (14%) 3 (33%)
ACVRL1 mutations 1 (7%) 1 (11%)
Negative 1 (7%) 0
Family history (n = 16) 10 (71%) 6 (67%)
Risk factors for VTE,
Recent surgery 1 (7%) 1 (11%) 0.62 (0.03–11.28)
Recent immobilization ≥4 days 4 (29%) 2 (22%) 1.40 (0. 20-9.87)
Cancer 1 (7%) 0 –
Prior VTE 1 (7%) 1 (11%) 0.62 (0.03–11.28)
None of the above 6 (43%) 6 (67%) 0.38 (0.07–2. 15)
Underlying conditions,
Prior ischemic stroke 3 (21%) 0 –
Atrial fibrillation 3 (21%) 0 –
Gastroduodenal ulcer 1 (7%) 0 –
Angiodisplasia in the GI tract 3 (21%) 0 –
Recent (< 30 days) major bleeding 0 3 (33%) –
Laboratory data,
Anemia 6 (43%) 5 (56%) 0.60 (0. 11-3.25)
CrCl levels < 30 mL/min 0 0 –
CrCl levels 30–60 mL/min 2 (14%) 3 (33%) 0.33 (0.04–2.56)
sPESI,
≥ 1 points 7 (50%) – –
Abbreviations: SD standard deviation, HHT hemorrhagic hereditary telangiectasia, ENG endoglin gene, ACVRL1 activin A receptor type II-like 1 gene, VTE venous
thromboembolism, GI gastrointestinal, sPESI simplified version of the Pulmonary Embolism Severity Index, CrCl creatinine clearance levels; 95%CI, 95%
confidence intervals
a Retrospective information added, not included in the RIETE Registry
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Patients, N 14 9
Duration of therapy,
Mean days (SD) 260 ± 254 243 ± 195 P = 0.867
Median days (IQR) 171 (111–335) 177 (86–475) P = 0.999
Initial therapy,
Unfractionated heparin 2 (14%) 0 –
Low-molecular-weight heparin 10 (71%) 9 (100%) –
Mean LMWH dose (IU/kg/day) 132 ± 50 151 ± 59 P = 0.474
LMWH doses < 100 IU/kg/day 4 (29%) 2 (22%) 2.33 (0.31–17.55)
Rivaroxaban 1 (7%) 0 –
Inferior vena cava filter (without anticoagulant therapy) 1 (7%) 0 –
Long-term therapy, 13 9
Low-molecular-weight heparin 7 (54%) 6 (67%) 0.58 (0. 10-3.40)
Mean LMWH dose (IU/kg/day) 135 ± 35 119 ± 43 P = 0.491
LMWH < 100 IU/kg/day 1 (8%) 2 (22%) 0.27 (0.02–3.52)
Vitamin K antagonists 5 (38%) 3 (33%) 1.25 (0. 21-7.41)
Rivaroxaban 1 (8%) 0 –
No anticoagulant drugs 0 0 –
Abbreviations: SD standard deviation, IQR interquartile range, LMWH low-molecular-weight heparin, IU international units, 95%CI, 95% confidence intervals
Table 3 Clinical outcomes during the course of anticoagulant therapy
Pulmonary embolism Deep vein thrombosis Rate ratio
(95%CI)N Events per 100
patient-years
N Events per 100
patient-years
Patients, N 14 9
Recurrent PE 0 – 0 – –
Recurrent DVT 0 – 1 16.67 (0. 22-92.72) –
Major bleeding 1 10.02 (0. 13-55.75) 1 16.67 (0. 22-92.72) 0.60 (0.04–9.61)
Site of major bleeding (days)a,
Epistaxis (32b) 0 – 1 16.67 (0. 22-92.72) –
GI (534) 1 10.02 (0. 13-55.75) 0 – –
Non-major bleeding 3 30.06 (6.04–87.83) 3 50 (10.05–146.1) 0.60 (0. 12-2.98)
Site of minor bleeding (days)a,
Epistaxis (9,31,179) 3 30.06 (6.04–87.83) 0 – –
Others (0b,5,50) 0 – 3 50 (10.05–146.1) –
Death 1 10.02 (0. 13-55.75) 0 – –
Causes of death,
Respiratory insufficiency 1 10.02 (0. 13-55.75) 0 – –
Abbreviations: PE pulmonary embolism, DVT deep vein thrombosis; 95%CI, 95% confidence intervals, GI gastrointestinal
a Days from index VTE diagnosis to bleeding event
b Receiving LMWH < 100 IU/kg/day
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Eighteen patients in our cohort (78%) had prior epi-
staxis, five had renal insufficiency, three had docu-
mented angiodisplasia in the GI tract and one patient
had a gastroduodenal ulcer. To what extent the use of
anticoagulant therapy could have influenced on the risk
for bleeding is unknown. Two of the three patients with
major epistaxis in the 30 days before the index VTE re-
peated epistaxis during the course of anticoagulation:
one of these had a major re-bleeding. Then, we cannot
assume that repeated epistaxis that happened during the
course of anticoagulant therapy were exclusively related
to anticoagulation, as epistaxis is an inherent feature of
HHT [3, 4, 9]. However, anticoagulation can increase the
duration and severity of epistaxis [12]. Unfortunately, we
have no monitoring ESS during anticoagulant treatment
to analyze this association.
In spite of the bleeding risk, some HHT patients also
suffer from thrombotic complications [10, 25–27]. Six
patients in our cohort developed the index VTE after be-
ing immobilized for an acute medical illness and two
had recent surgery, but only three of them did receive
VTE prophylaxis. We hypothesize that the attending
doctors might have been concerned about the risk for
bleeding. In the on-line survey of HHT patients with
self-reported VTE, 76% of them had a risk factor for
VTE [13]. There is consistent evidence on the reduction
of VTE using prophylaxis in at-risk patients, with very
low increase in the risk for bleeding [28], but we do not
know the potential benefit of VTE prophylaxis in at-risk
patients with HHT. Further research is necessary to de-
fine prophylactic strategies in this frequently hospitalized
HHT population. For these provoked VTE events, anti-
coagulant therapy for only 3 months is recommended
[29].
Our study has a number of limitations. First, the pro-
portion of patients with HHT in our cohort was most
likely conservative because some cases might have been
missed. Second, we were not able to retrospectively col-
lect genetic study and reassess Curaçao criteria in all pa-
tients [7, 8]. Nonetheless, the high percentage of
recurrent epistaxis and first degree relatives with HHT
in our patients, support the HHT diagnosis. Third, our
study was not designed for assessment of comparative
effectiveness of management strategies in patients with
HHT. Since all patients with HHT in our cohort re-
ceived anticoagulant therapy, we are unable to compare
the potential advantages of the different therapeutic ap-
proaches. However, our study provides important in-
sights into the outcomes of HTT patients with VTE.
Fourth, the ESS has been retrospectively calculated after
some time, being a likely cause of ascertainment bias. Fi-
nally, although many of the studies from the RIETE
registry were designed with broad or detailed a priori
plans, HHT is a rare disease and the decisions to explore
several of the data elements were based on post-hoc
plans and analyses. However, to our knowledge, these
data represent the largest series of patients with HHT
and objectively confirmed VTE. Moreover, the main
strengths of our study are the strict and objectively diag-
nostic criteria for VTE, the long-term follow-up period
and the objectively established outcomes reported
(bleeding, recurrent symptomatic VTE and mortality).
Conclusions
In conclusion, the use of anticoagulant therapy for VTE
in patients with HHT may certainly increase the risk for
bleeding, but it barely influences on mortality. Most
bleeds come from nasal or digestive telangiectasia and
not from large HHT-related vascular malformations. So,
although bleeding events are more frequent than VTE
recurrences, the use of anticoagulation was not associ-
ated with fatal bleeding. PE is the most common presen-
tation of VTE in patients with HHT. Almost half of our
HHT patients had a risk factor for VTE. Patients with
HHT should be carefully evaluated for nosebleeds when
needing anticoagulant treatment. The optimal type, dose
and duration of anticoagulant therapy for VTE in pa-
tients with HHT needs further investigation.
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